Bristol Myers Squibb announces that the phase 3 CheckMate-73L trial failed to meet its primary endpoint of progression-free survival in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC).

The pharmaceutical company recalls that CheckMate -73L evaluated its Opdivo with concomitant chemoradiotherapy (CCRT) followed by Opdivo plus Yervoy versus CCRT followed by durvalumab in patients with unresectable stage III NSCLC.

Adverse events were generally consistent with the known profiles of each component of the regimen. Bristol Myers will conduct a full evaluation of the data and work with the investigators to share the results with the scientific community.

Copyright (c) 2024 CercleFinance.com. All rights reserved.